TABLE 3:
Hazard ratios and confidence intervals by attribute
| Attribute | Grade III Gliomas |
Glioblastomas |
|||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P Value | HR | 95% CI | P Value | ||
| Clinical | |||||||
| Age | 3.74 | 1.09–12.9 | .036 | 2.29 | 1.35–3.86 | .002 | |
| KPS | 0.96 | 0.93–0.99 | .006 | 0.98 | 0.96–0.99 | .005 | |
| Oligodendroglioma component | 1.06 | 0.55–2.07 | .854 | 0.58 | 0.34–0.99 | .047 | |
| Resection | 1.22 | 0.67–2.23 | .517 | 1.08 | 0.85–1.37 | .530 | |
| Imaging | |||||||
| Enhancing rim | 1.68 | 0.34–8.37 | .519 | 1.16 | 0.73–1.84 | .522 | |
| SE | 0.79 | 0.38–1.61 | .508 | 1.04 | 0.66–1.63 | .863 | |
| CE | 3.30 | 0.71–15.3 | .127 | 1.53 | 0.21–11.1 | 0.68 | |
| ECM | 2.45 | 0.76–7.87 | .134 | 1.33 | 0.81–2.21 | .264 | |
| TCM | 2.45 | 0.76–7.87 | .134 | 1.31 | 0.72–2.36 | .374 | |
| Location | 0.97 | 0.63–1.52 | .914 | 1.04 | 0.88–1.23 | .639 | |
| Multifocal | 18.7 | 3.06–115 | .002 | 4.34 | 2.11–8.92 | .001 | |
| Necrosis | 4.43 | 1.35–14.6 | .014 | 1.24 | 0.30–5.09 | .764 | |
| nCET | 0.05 | 0.01–0.55 | .014 | 0.55 | 0.33–0.92 | .023 | |
| EM | 0.32 | 0.07–1.35 | .121 | 0.64 | 0.37–1.12 | .120 | |
| NEM | 2.95 | 0.85–10.3 | .089 | ||||
| Satellites | 5.18 | 1.11–24.1 | .036 | 1.74 | 1.03–2.93 | .038 | |
| Side | 0.80 | 0.17–3.79 | .782 | 1.29 | 0.79–2.07 | .300 | |
| Size | 1.16 | 0.90–1.50 | .235 | 1.05 | 0.94–1.17 | .393 | |
| Cyst | 0.03 | 0.00–20.8 | .302 | 0.92 | 0.46–1.80 | .799 | |
| Edema | 1.99 | 0.79–3.99 | .158 | 1.62 | 1.18–2.22 | .003 | |
Note.—HR indicates hazard ratio (of dying); KPS, Karnofsky performance status; SE, solid enhancement; CE, contrast enhancement; ECM, edema crosses midline; TCM, tumor crosses midline; nCET, noncontrast-enhancing tumor; EM, enhancing margin; NEM, nonenhancing margin.